Sonoma Pharmaceuticals, Inc. Forecast, price target & analysts
Sonoma Pharmaceuticals, Inc. Target price 2025 - Analyst rating & recommendation
Sonoma Pharmaceuticals, Inc. Classifications & Recommendation:
Sonoma Pharmaceuticals, Inc. Price Target
| Target Price | $17.34 |
| Price | $2.85 |
| Potential |
509.49%
register free of charge
|
| Number of Estimates | 3 |
|
3 Analysts have issued a price target Sonoma Pharmaceuticals, Inc. 2026 .
The average Sonoma Pharmaceuticals, Inc. target price is $17.34.
This is
509.49%
register free of charge
$17.85
527.42%
register free of charge
$17.17
503.51%
register free of charge
|
|
| A rating was issued by 7 analysts: 6 Analysts recommend Sonoma Pharmaceuticals, Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Sonoma Pharmaceuticals, Inc. stock has an average upside potential 2026 of
509.49%
register free of charge
|
Sales and Margin forecast 2026, 2027 & 2028
| Mar '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 14.29 | 19.79 |
| 12.17% | 38.52% | |
| Net Margin | -24.21% | -15.01% |
| 36.27% | 38.01% |
3 Analysts have issued a sales forecast Sonoma Pharmaceuticals, Inc. 2026 . The average Sonoma Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
Revenue Estimates
| 2025 | $14.3m | 12.17% |
|---|---|---|
| 2026 |
$19.8m
38.52%
Unlock
|
|
3 Sonoma Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2026. The average Sonoma Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2025 | $-3.5m | 28.51% |
|---|---|---|
| 2026 |
$-3.0m
14.16%
Unlock
|
|
Net Margin
| 2025 | -24.21% | 36.27% |
|---|---|---|
| 2026 |
-15.01%
38.01%
Unlock
|
|
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 & 2028
| Mar '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.79 | -1.82 |
| 73.78% | 34.77% | |
| P/E | negative | |
| EV/Sales | negative |
3 Analysts have issued a Sonoma Pharmaceuticals, Inc. forecast for earnings per share. The average Sonoma Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2025 | $-2.79 | 73.78% |
|---|---|---|
| 2026 |
$-1.82
34.77%
Unlock
|
|
P/E ratio
| Current | -1.33 | 97.33% |
|---|---|---|
| 2026 |
-1.56
17.35%
Unlock
|
|
Based on analysts' sales estimates for 2026, the Sonoma Pharmaceuticals, Inc. stock is valued at an EV/Sales of
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | -0.03 | 130.00% |
|---|---|---|
| 2026 |
-0.02
19.33%
Unlock
|
|
P/S ratio
| Current | 0.33 | 3.35% |
|---|---|---|
| 2026 |
0.24
27.88%
Unlock
|
|
Sonoma Pharmaceuticals, Inc....
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
